Skip to content

H.R. 4005 · 118th Congress (2023–2025)

Naloxone Affordability Act of 2023

This bill requires the Government Accountability Office to study access to and affordability of naloxone (a medication that temporarily reverses opioid overdoses). The study must address matters related to out-of-pocket costs that consumers pay for naloxone and coverage for naloxone as an over-the-counter drug through Medicare, Medicaid, and private health insurance.

Historically, naloxone required a prescription and so was typically covered by health insurance. However, the Food and Drug Administration approved Narcan (a naloxone hydrochloride nasal spray) for use without a prescription on March 29, 2023, and health insurance does not generally cover over-the-counter medications.


Show official title

To direct the Comptroller General of the United States to conduct a study on naloxone access.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 4005’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Ann M. Kuster (D-NH-2)
Cosponsors
2 cosponsors

2 original · 0 later

  1. Rep. Lisa Blunt Rochester (D-DE)· Original · Jun 12, 2023
  2. Rep. Angie Craig (D-MN-2)· Original · Jun 12, 2023
Policy area
Health
Subjects
  • Congressional oversight
  • Drug therapy
  • Drug, alcohol, tobacco use
  • Government studies and investigations
  • Health care costs and insurance
  • Health care coverage and access
  • Medicaid
  • Medicare
  • 1 more
    • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Jun 12, 2023 – Jun 16, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Jun 12, 2023
  2. HouseHealthReferred Jun 16, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Naloxone Affordability Act of 2023

    Display title, Short title · Introduced in House

  2. To direct the Comptroller General of the United States to conduct a study on naloxone access.

    Official title · Introduced in House